(NASDAQ: VIGL) Vigil Neuroscience's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 37.22%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 9.95%.
Vigil Neuroscience's revenue in 2024 is $0.On average, 1 Wall Street analysts forecast VIGL's revenue for 2025 to be $1,773,603,683, with the lowest VIGL revenue forecast at $1,773,603,683, and the highest VIGL revenue forecast at $1,773,603,683. On average, 1 Wall Street analysts forecast VIGL's revenue for 2026 to be $3,181,887,854, with the lowest VIGL revenue forecast at $3,181,887,854, and the highest VIGL revenue forecast at $3,181,887,854.
In 2027, VIGL is forecast to generate $3,642,671,519 in revenue, with the lowest revenue forecast at $1,970,545,478 and the highest revenue forecast at $5,314,797,560.